ContraFect Corp (NASDAQ:CFRX) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 493,405 shares, a decline of 46.6% from the January 15th total of 923,895 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average daily trading volume, of 813,746 shares, the short-interest ratio is presently 0.6 days.
Separately, ValuEngine raised ContraFect from a “hold” rating to a “buy” rating in a research note on Tuesday, November 6th.
In other ContraFect news, major shareholder Fosun Pharmaceutical Shanghai sold 600,000 shares of the business’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $2.04, for a total transaction of $1,224,000.00. Following the transaction, the insider now owns 7,900,000 shares of the company’s stock, valued at $16,116,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.70% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in ContraFect by 108.1% during the third quarter. JPMorgan Chase & Co. now owns 167,182 shares of the biotechnology company’s stock worth $346,000 after buying an additional 86,848 shares during the last quarter. Oracle Investment Management Inc. lifted its stake in shares of ContraFect by 31.8% in the 3rd quarter. Oracle Investment Management Inc. now owns 4,250,384 shares of the biotechnology company’s stock valued at $8,798,000 after purchasing an additional 1,025,651 shares during the last quarter. AXA lifted its stake in shares of ContraFect by 196.0% in the 3rd quarter. AXA now owns 1,664,781 shares of the biotechnology company’s stock valued at $3,446,000 after purchasing an additional 1,102,264 shares during the last quarter. Federated Investors Inc. PA lifted its stake in shares of ContraFect by 6.8% in the 3rd quarter. Federated Investors Inc. PA now owns 6,407,500 shares of the biotechnology company’s stock valued at $13,264,000 after purchasing an additional 407,500 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of ContraFect by 109.8% in the 3rd quarter. Renaissance Technologies LLC now owns 420,700 shares of the biotechnology company’s stock valued at $871,000 after purchasing an additional 220,200 shares during the last quarter. 56.06% of the stock is currently owned by institutional investors.
NASDAQ CFRX opened at $0.41 on Thursday. The firm has a market cap of $32.96 million, a price-to-earnings ratio of -1.11 and a beta of -0.48. ContraFect has a fifty-two week low of $0.35 and a fifty-two week high of $2.93.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Highlight Press and is owned by of Highlight Press. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://highlightpress.com/2019/02/14/contrafect-corp-cfrx-short-interest-down-46-6-in-january.html.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Article: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.